{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T07:04:00Z","timestamp":1682665440197},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"47","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1097\/md.0000000000008922","type":"journal-article","created":{"date-parts":[[2017,11,22]],"date-time":"2017-11-22T19:13:26Z","timestamp":1511378006000},"page":"e8922","source":"Crossref","is-referenced-by-count":3,"title":["A recurrence-free survivor with chemotherapy-refractory small cell lung cancer after pneumonectomy"],"prefix":"10.1097","volume":"96","author":[{"given":"Yong","family":"Pan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng-Wei","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Bin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-121-20210309","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/cncr.29098","article-title":"Small cell lung cancer: where do we go from here?","volume":"121","author":"Byers","year":"2015","journal-title":"Cancer"},{"key":"R2-121-20210309","doi-asserted-by":"crossref","first-page":"4106","DOI":"10.1200\/JCO.2015.63.7918","article-title":"Treatment of small-cell lung cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline","volume":"33","author":"Rudin","year":"2015","journal-title":"J Clin Oncol"},{"key":"R5-121-20210309","doi-asserted-by":"crossref","first-page":"e3598","DOI":"10.1097\/MD.0000000000003598","article-title":"The use of apatinib in treating nonsmall-cell lung cancer: case report and review of literature","volume":"95","author":"Ding","year":"2016","journal-title":"Medicine (Baltimore"},{"key":"R6-121-20210309","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1177\/1758834013517413","article-title":"Relapsed small cell lung cancer: treatment options and latest developments","volume":"6","author":"Asai","year":"2014","journal-title":"Ther Adv Med Oncol"},{"key":"R7-121-20210309","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.cllc.2016.05.014","article-title":"SCLC-state of the art and what does the future have in store?","volume":"17","author":"Kahnert","year":"2016","journal-title":"Clin Lung Cancer"},{"key":"R8-121-20210309","first-page":"39","article-title":"Small cell lung cancer (SCLC): no treatment advances in recent years","volume":"5","author":"Koinis","year":"2016","journal-title":"Transl Lung Cancer Res"},{"key":"R9-121-20210309","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/978-3-319-24932-2_9","article-title":"Personalized therapy of small cell lung cancer","volume":"890","author":"Schneider","year":"2016","journal-title":"Adv Exp Med Biol"},{"key":"R10-121-20210309","doi-asserted-by":"crossref","first-page":"e6412","DOI":"10.1097\/MD.0000000000006412","article-title":"Angiogenesis inhibitors for the treatment of small cell lung cancer (SCLC): a meta-analysis of 7 randomized controlled trials","volume":"96","author":"Li","year":"2017","journal-title":"Medicine (Baltimore"},{"key":"R11-121-20210309","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.cllc.2016.05.008","article-title":"No advantage in survival with targeted therapies as maintenance in patients with limited and extensive-stage small cell lung cancer: a literature-based meta-analysis of randomized trials","volume":"17","author":"Roviello","year":"2016","journal-title":"Clin Lung Cancer"},{"key":"R12-121-20210309","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1093\/annonc\/mdv065","article-title":"Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial\u2020","volume":"26","author":"Pujol","year":"2015","journal-title":"Ann Oncol"},{"key":"R13-121-20210309","doi-asserted-by":"crossref","first-page":"615.e8","DOI":"10.1016\/j.cllc.2017.05.007","article-title":"A randomized, placebo-controlled, phase 1b\/2 study of rilotumumab or ganitumab in combination with platinum-based chemotherapy as first-line treatment for extensive-stage small-cell lung cancer","volume":"18","author":"Glisson","year":"2017","journal-title":"Clin Lung Cancer"},{"key":"R14-121-20210309","first-page":"513","article-title":"Genomic profiling of small-cell lung cancer: the era of targeted therapies","volume":"45","author":"Umemura","year":"2015","journal-title":"Jpn J Clin Oncol"},{"key":"R15-121-20210309","first-page":"51","article-title":"Targeted drugs in small-cell lung cancer","volume":"5","author":"Santarpia","year":"2016","journal-title":"Transl Lung Cancer Res"},{"key":"R16-121-20210309","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1200\/JOP.2015.009068","article-title":"Multimodality therapy for limited-stage small-cell lung cancer","volume":"12","author":"Almquist","year":"2016","journal-title":"J Oncol Pract"},{"key":"R17-121-20210309","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.ejso.2016.04.063","article-title":"A review of the role of surgery for small cell lung cancer and the potential prognostic value of enumeration of circulating tumor cells","volume":"42","author":"Hamilton","year":"2016","journal-title":"Eur J Surg Oncol"},{"key":"R18-121-20210309","first-page":"CD011917","article-title":"Surgery for limited-stage small-cell lung cancer","volume":"4","author":"Barnes","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"R19-121-20210309","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.21037\/jtd.2017.03.88","article-title":"Salvage surgery after high-dose radiotherapy","volume":"9","author":"Van Breussegem","year":"2017","journal-title":"J Thorac Dis"},{"key":"R20-121-20210309","doi-asserted-by":"crossref","first-page":"65","DOI":"10.5761\/atcs.ra.16-00019","article-title":"Current topics on salvage thoracic surgery in patients with primary lung cancer","volume":"22","author":"Uramoto","year":"2016","journal-title":"Ann Thorac Cardiovasc Surg"},{"key":"R21-121-20210309","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1200\/JCO.2003.09.130","article-title":"Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597","volume":"21","author":"Masters","year":"2003","journal-title":"J Clin Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000008922","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:44:38Z","timestamp":1620960278000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201711270-00121"}},"subtitle":["A case report and review of the literature"],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":19,"journal-issue":{"issue":"47","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000008922","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]}}}